Sucralfate, a medication used to treat and prevent peptic ulcers, was developed in the 1970s and approved for medical use in the late 1980s. Its history is marked by its effectiveness in promoting ulcer healing, but also by considerations regarding its interactions with other medications and absorption issues, which led to recommendations on timing of administration relative to other drugs. Sucralfate, a gastrointestinal mucosal protectant used to treat ulcers and gastritis, was approved in the United States in 1981 and is included in multiple treatment regimens for ulcer management. Its development featured early clinical trials focused on ulcer healing rates and a notable expanded access to patients with severe ulcer disease, permitting early monitoring of safety and efficacy.
BRAND NAMES
Carafate – the most widely known brand in the United States
Sulcrate – used in some countries outside the U.S.
Ulcar – available in parts of Asia and Europe
Antepsin – another regional brand name
MECHANISM OF ACTION
Sucralfate works by forming a viscous, sticky barrier that selectively adheres to ulcers and erosions in the stomach and duodenum. This protective coating shields the damaged mucosa from acid, pepsin, and bile salts, allowing the tissue to heal. Additionally, it stimulates local production of bicarbonate and prostaglandins, which enhance mucosal defense. Because it acts locally and is minimally absorbed, sucralfate primarily protects and heals the gastrointestinal lining without significant systemic effects.
PHARMACOKINETICS
Absorption
Sucralfate is minimally absorbed from the gastrointestinal tract, remaining largely in the stomach and duodenum where it exerts its protective effects. Only a small fraction enters the bloodstream, which limits systemic exposure and reduces the risk of systemic side effects.
Distribution
Sucralfate is largely confined to the gastrointestinal tract, especially the stomach and duodenum, where it adheres to ulcer sites. Only trace amounts reach the systemic circulation, so its action is primarily local rather than systemic.
Metabolism
Sucralfate undergoes minimal metabolism in the body. It primarily acts locally in the gastrointestinal tract without significant chemical breakdown in the liver or other organs. Any absorbed portion is largely excreted unchanged in the urine.
Elimination
Sucralfate is primarily eliminated through the feces as most of the drug remains unabsorbed in the gastrointestinal tract. Only a very small amount that is absorbed systemically is excreted in the urine, so elimination is largely local and does not rely on significant liver metabolism.
PHARMACODYNAMICS
Sucralfate works by forming a sticky barrier that adheres to ulcers and erosions in the stomach and duodenum, protecting them from acid, pepsin, and bile salts. It also stimulates local secretion of bicarbonate and prostaglandins, which strengthen mucosal defenses and promote healing. Its action is primarily local, with minimal systemic effects due to poor absorption.
ADMINISTRATION
Sucralfate is given orally as tablets or suspension, usually 1 hour before meals and at bedtime. Tablets should be swallowed whole with water, and the suspension shaken well before use. It is important to separate sucralfate from other medications by at least 2 hours to avoid interference with their absorption.
DOSAGE AND STRENGTH
Tablets: 1 gram each
Oral suspension: 1 gram per 10 mL
Usual Adult Dosage:
For active duodenal ulcers: 1 gram four times daily (before meals and at bedtime) for 4–8 weeks
For maintenance therapy: 1 gram twice daily
Pediatric Dosage:
Typically 40–60 mg/kg/day divided into 4 doses, depending on the child’s condition and weight.
DRUG INTERACTIONS
Sucralfate may reduce the absorption of drugs like fluoroquinolones, tetracyclines, digoxin, and iron. It should be taken at least 2 hours apart from other oral medications.
FOOD INTERACTIONS
Sucralfate is best taken on an empty stomach, usually 1 hour before meals or at bedtime. Food may reduce its ability to adhere to ulcers, decreasing its effectiveness. There are no specific dietary restrictions, but spacing it from meals helps maximize its protective action.
CONTRAINDICATIONS
Sucralfate is contraindicated in patients with hypersensitivity, severe renal impairment, or gastrointestinal obstruction.
SIDE EFFECTS
Constipation
Dry mouth
Nausea
Indigestion or upset stomach
Uncommon but more serious side effects:
Aluminum toxicity (in patients with renal impairment)
Allergic reactions (rash, itching, swelling)
Difficulty breathing or swallowing (rare)
TOXICITY
Sucralfate has low toxicity and is generally safe. In patients with severe renal impairment, aluminum accumulation may occur, causing constipation, nausea, or neurological effects.
